Day: March 2, 2023

Clinical data updates expected in 2023 for all three programs NC525 (LAIR-1 mAb) dosed first patient in a Phase 1 trial in acute myeloid leukemia (AML) Ended 2022 with approximately $160 million in cash that is expected to fund operations into mid-2025BELTSVILLE, Md., March 02, 2023 (GLOBE NEWSWIRE) — NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today provided a business update and reported full year 2022 financial results. “2023 is expected to be a significant year for NextCure as we are anticipating data updates on all three of our clinical programs, starting with NC410, which targets the extracellular matrix,” said Michael Richman, NextCure’s president and chief executive...

Grew revenue 134% and increased instruments shipped 129% year over year REDWOOD CITY, Calif., March 02, 2023 (GLOBE NEWSWIRE) — Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today reported financial results for the fourth quarter and full year ended December 31, 2022. “I am extremely proud of the Seer team and our accomplishments in our first year of broad commercial availability. The Proteograph Product Suite has been performing exceptionally well in the hands of customers, enabling them to obtain biological insights that were not previously possible. Customers are consistently seeing deep protein coverage that is measured quantitatively, accurately, and with precision – in a way that is scalable and enables unprecedented studies,” said Omid Farokhzad, CEO and...

Continued successful launch of IBSRELA, ending FY 2022 with $15.6 million in net product sales Resubmission of XPHOZAH New Drug Application expected in early Q2 2023 Company ends Q4 with approximately $123.9 million in cash and investments Conference call scheduled for 4:30 PM Eastern Time WALTHAM, Mass., March 02, 2023 (GLOBE NEWSWIRE) — Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today reported financial results for the fourth quarter and full year ended December 31, 2022 and provided a business update. “2022 was a remarkable year for Ardelyx, having met significant milestones that demonstrate our deep and profound commitment to bringing our novel mechanism products to patients...

AUSTIN, Texas, March 02, 2023 (GLOBE NEWSWIRE) — Ideal Power Inc. (“Ideal Power” or the “Company”) (Nasdaq: IPWR), pioneering the development and commercialization of the highly efficient and broadly patented B-TRAN™ bidirectional semiconductor power switch, reported results for its fourth quarter and full year ended December 31, 2022. “Ideal Power accomplished a great deal in 2022 and early 2023. The recent launch of our first commercial product, the SymCool™ Power Module, marks a pivotal development for our B-TRAN™ technology,” said Dan Brdar, President and Chief Executive Officer of Ideal Power. “Our intense focus continues toward B-TRAN™ commercialization. We believe B-TRAN™ has the potential to displace conventional power semiconductor solutions in many applications including electric vehicles...

Closes year strong with same-store-sales up 18.9% and record AUVs of $24,144 for the fourth quarter Delivers record revenue with full-year same-store sales growth of 18.5%, and significant improvement in profitability with full-year net income of $4.3 million and Adjusted EBITDA of $15.7 million Provides first quarter and full year 2023 outlook for continued growth and momentum CHICAGO, March 02, 2023 (GLOBE NEWSWIRE) — Potbelly Corporation (NASDAQ: PBPB), (“Potbelly” or the “Company”) the iconic neighborhood sandwich shop concept, today reported financial results for the fourth fiscal quarter and full year ended December 25, 2022. Fiscal 2022 Results Key highlights for the quarter ended December 25, 2022, compared to December 26, 2021:Total revenues increased by 17% to $120.2 million compared to $102.8 million, with record...

SAN DIEGO, March 02, 2023 (GLOBE NEWSWIRE) — Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today highlighted recent corporate achievements and reported financial results for the fourth quarter and full year ended December 31, 2022. “2022 was a pivotal year for Singular Genomics. It was a year in which we achieved important milestones, overcame challenges, and ultimately ended on a strong note with five G4 systems in market. Most importantly, the business is set up for success with the right team, the right product, and the right opportunity. I am tremendously proud of the entire Singular team,” said Drew Spaventa, Chairman and Chief Executive Officer of Singular Genomics. “In 2023, we will remain...

NEW YORK, March 02, 2023 (GLOBE NEWSWIRE) — Silvercrest Asset Management Group Inc. (NASDAQ: SAMG) (the “Company” or “Silvercrest”) today reported the results of its operations for the quarter and year ended December 31, 2022. Business Update Silvercrest finished a volatile fourth quarter and calendar year 2022 with Total Assets under Management (“AUM”) of $28.9 billion and Discretionary AUM of $20.9 billion. Total AUM declined 10.5% during the calendar year 2022. Discretionary AUM, which primarily drives revenue, declined 16.7% during the year 2022. Revenue consequently fell 15.7% and 6.4% for the fourth quarter and full year 2022, respectively, compared with 2021. This decline in revenue significantly affected Adjusted EBITDA1 and Adjusted Diluted Earnings per Share1, 2. Adjusted EBITDA1 declined to $4.4 million and $32.0 million...